AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29031778 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg orally once a day for 6 years
Number of subjects: 1860
Study 29031778 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg orally once a day for 3 years
Number of subjects: 1860
Study 26156156 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-4
Number of subjects: 165
Study 26156156 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-4 + Cetuximab
Number of subjects: 165
Study 26156156 — intervention group
Group type: COMPARATOR
Intervention: Control arm (colectomy and adjuvant chemotherapy)
Number of subjects: 165
Study 26156156 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (FOLFOX-4) for RAS mutated patients
Number of subjects: 165
Study 23041003 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP-ATP III definition of MetS
Number of subjects: 5198
Study 23041003 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA/NHLBI definition of MetS
Number of subjects: 5198
Study 23041003 — intervention group
Group type: EXPERIMENTAL
Intervention: IDF definition of MetS
Number of subjects: 5198
Study 23041003 — intervention group
Group type: EXPERIMENTAL
Intervention: JIS definition of MetS
Number of subjects: 5198
Study 23041003 — intervention group
Group type: EXPERIMENTAL
Intervention: All definitions of MetS
Number of subjects: 5198
Study 21217408 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized free-form PAL spectacles
Number of subjects: 95
Study 21217408 — intervention group
Group type: COMPARATOR
Intervention: Standard non-free-form PAL spectacles
Number of subjects: 95
Study 18511470 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg rhTSH
Number of subjects: 24
Study 16970138 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin every other day
Number of subjects: 39876
Study 16970138 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet every other day
Number of subjects: 39876
Study 16970138 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU of vitamin E on intervening days
Number of subjects: 39876
Study 16970138 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule on intervening days
Number of subjects: 39876
Study 15004251 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (calcium-channel blocker)
Number of subjects: 77
Study 15004251 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (AT1-receptor blocker)
Number of subjects: 77
Study 15004251 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (NO synthase inhibitor)
Number of subjects: 77
Study 11075941 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg twice daily for 5 days
Number of subjects: 235
Study 11075941 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg once or twice daily for 7 days
Number of subjects: 235
Study 11075941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 9126182 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing attachment level change over one year
Number of subjects: 0
Study 9126182 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing attachment level change over two years
Number of subjects: 0
Study 9126182 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year change in probing attachment level
Number of subjects: 0
Study 9126182 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-year change in probing attachment level
Number of subjects: 0
Study 1555688 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hormone replacement therapy (HRT) regimen
Number of subjects: 18
Study 1555688 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard HRT regimen
Number of subjects: 18
Study 1555688 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced doses of estradiol valerate (1/3 of standard)
Number of subjects: 18
Study 1555688 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced doses of progesterone (1/5 of standard)
Number of subjects: 18
Study 3930255 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg dose of UDCA
Number of subjects: 12
Study 3930255 — intervention group
Group type: EXPERIMENTAL
Intervention: 250, 500, or 750 mg doses of UDCA
Number of subjects: 12
Study 3930255 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (various doses)
Number of subjects: 12
Study 3930255 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of UDCA
Number of subjects: 12
Study 3930255 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated daily doses of UDCA
Number of subjects: 12
Study 30737555 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (12 mg)
Number of subjects: 13
Study 30737555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isocaloric)
Number of subjects: 13
Study 30485351 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessible video for students with visual impairments
Number of subjects: 228
Study 30485351 — intervention group
Group type: COMPARATOR
Intervention: Non-accessible video
Number of subjects: 228
Study 30485351 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessible video
Number of subjects: 228
Study 27039236 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol (BUD/FM) 320/9 μg via pressurized metered-dose inhaler (pMDI)
Number of subjects: 386
Study 27039236 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 320 μg via pMDI
Number of subjects: 386
Study 27039236 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (FM) 9 μg via dry-powder inhaler
Number of subjects: 386
Study 27039236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 24562799 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of MAp44 in MI patients (18% higher than control group, p<0.001)
Number of subjects: 192
Study 24562799 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of MASP-1 in MI patients (elevated, p=0.002)
Number of subjects: 192
Study 24562799 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of MASP-3 in MI patients (elevated, p<0.001)
Number of subjects: 192
Study 24562799 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group plasma levels of MAp44, MASP-1, and MASP-3
Number of subjects: 192
Study 22854910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation training intervention
Number of subjects: 108
Study 20106824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ramipril at 5 mg/day, valsartan at 80 mg/day and increased furosemide dosage
Number of subjects: 18
Study 20106824 — intervention group
Group type: COMPARATOR
Intervention: Combined ramipril at 5 mg/day and valsartan at 80 mg/day
Number of subjects: 18
Study 20106824 — intervention group
Group type: COMPARATOR
Intervention: Combined ramipril at 10 mg/day and valsartan at 160 mg/day
Number of subjects: 18
Study 20106824 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic dosage uptitration
Number of subjects: 18
Study 17394248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of selected CD133(+) and CD133(−) CD34(+) progenitor cells
Number of subjects: 24
Study 17394248 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (Control)
Number of subjects: 24
Study 16359280 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 50
Study 16359280 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 50
Study 16359280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12068300 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional musicians
Number of subjects: 37
Study 12068300 — intervention group
Group type: COMPARATOR
Intervention: Non‐musicians
Number of subjects: 37
Study 10215718 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine colour (scored on an eight-point scale)
Number of subjects: 40
Study 10215718 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective assessment of urine colour by intensive care nurses
Number of subjects: 40
Study 8583437 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg daily
Number of subjects: 22
Study 8583437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2243411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter monitoring
Number of subjects: 102
Study 2243411 — intervention group
Group type: COMPARATOR
Intervention: Central venous catheter monitoring
Number of subjects: 102
Study 28480 — intervention group
Group type: EXPERIMENTAL
Intervention: novel pyridylbenzodiazepine
Number of subjects: 18
Study 28480 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 18
Study 28480 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 31195307 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic evaluation of nasal cavity, pharynx and larynx
Number of subjects: 129
Study 29211699 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (RG)
Number of subjects: 163
Study 29211699 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic gastrectomy (LG)
Number of subjects: 163
Study 26282658 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (100 mg twice per day) plus Paclitaxel (80 mg/m² on days 1, 8, and 15 of every 28-day cycle)
Number of subjects: 124
Study 26282658 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Paclitaxel (80 mg/m² on days 1, 8, and 15 of every 28-day cycle)
Number of subjects: 124
Study 26282658 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (200 mg twice per day) as maintenance therapy
Number of subjects: 124
Study 26282658 — intervention group
Group type: COMPARATOR
Intervention: Placebo as maintenance therapy
Number of subjects: 124
Study 26282658 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib/paclitaxel in ATMlow population
Number of subjects: 124
Study 26282658 — intervention group
Group type: COMPARATOR
Intervention: Placebo/paclitaxel in ATMlow population
Number of subjects: 124
Study 25103522 — intervention group
Group type: EXPERIMENTAL
Intervention: Interesterified palm olein (IPO)
Number of subjects: 11
Study 25103522 — intervention group
Group type: COMPARATOR
Intervention: Native palm olein (NPO)
Number of subjects: 11
Study 22074414 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring the impact of bipolar disorder
Number of subjects: 21
Study 19416224 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin 3 microg/kg of body weight/day
Number of subjects: 0
Study 19416224 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin 10 microg/kg of body weight/day
Number of subjects: 0
Study 19416224 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin 30 microg/kg of body weight/day
Number of subjects: 0
Study 19416224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17582923 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (4.5 g to 9 g a day)
Number of subjects: 690
Study 17582923 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (at least 6 g a day)
Number of subjects: 690
Study 17582923 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (continuing treatment)
Number of subjects: 690
Study 17582923 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 690
Study 15693087 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E (500 mg vitamin C and 800 IU vitamin E daily)
Number of subjects: 39
Study 15693087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 11923638 — intervention group
Group type: COMPARATOR
Intervention: P792 (0.0065, 0.013, 0.026, and 0.039 mmol/kg)
Number of subjects: 32
Study 9785922 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic linear salpingostomy (group 1)
Number of subjects: 30
Study 9785922 — intervention group
Group type: COMPARATOR
Intervention: Single-dose methotrexate (group 2)
Number of subjects: 30
Study 7665720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day (Lo group)
Number of subjects: 34
Study 7665720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P1 group)
Number of subjects: 34
Study 2652569 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 (5 mg intravenous bolus)
Number of subjects: 88
Study 2652569 — intervention group
Group type: COMPARATOR
Intervention: MAG (20 mg/kg/day)
Number of subjects: 88
Study 963865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal betamethasone valerate aerosol for 28 days
Number of subjects: 30
Study 963865 — intervention group
Group type: COMPARATOR
Intervention: Oral antihistamine compound
Number of subjects: 30
Study 30773551 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldspathic porcelain (Noritake®) by slurry molding
Number of subjects: 30
Study 30773551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium disilicate glass ceramic (IPS E.max® Press) by heat‐pressed
Number of subjects: 30
Study 30773551 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldspar porcelain block (VITA Mark II®) by CAD/CAM
Number of subjects: 30
Study 30773551 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia‐reinforced glass ceramic (VITA Suprinity®) by CAD/CAM
Number of subjects: 30
Study 30773551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid ceramic with a ceramic‐polymer network (VITA Enamic®) by CAD/CAM
Number of subjects: 30
Study 28778464 — intervention group
Group type: COMPARATOR
Intervention: GET 73 single ascending doses (10, 30, 100, 300, 450, 600 mg)
Number of subjects: 80
Study 28778464 — intervention group
Group type: COMPARATOR
Intervention: GET 73 multiple ascending doses (100, 300, 450 mg twice a day)
Number of subjects: 80
Study 28778464 — intervention group
Group type: COMPARATOR
Intervention: GET 73 (single and repeated doses)
Number of subjects: 80
Study 25494871 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (48-hour duration)
Number of subjects: 0
Study 25494871 — intervention group
Group type: COMPARATOR
Intervention: Exercise (3 intensities)
Number of subjects: 0
Study 24292304 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (3 doses of 250mg/kg per dose, 24 hours apart)
Number of subjects: 50
Study 24292304 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (3 doses, 24 hours apart)
Number of subjects: 50
Study 24292304 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion
Number of subjects: 50
Study 24292304 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 50
Study 21440036 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 3009
Study 21440036 — intervention group
Group type: COMPARATOR
Intervention: TIV
Number of subjects: 3009
Study 19624440 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) self-administered vaginally at home
Number of subjects: 350
Study 19624440 — intervention group
Group type: COMPARATOR
Intervention: Placebo self-administered vaginally at home
Number of subjects: 350
Study 16711497 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous posterior tibial nerve block with 0.375% ropivacaine (5 mL x h(‐1))
Number of subjects: 40
Study 16711497 — intervention group
Group type: COMPARATOR
Intervention: Oral analgesia (metamizole 575 mg/6 h p.o.)
Number of subjects: 40
Study 16711497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received 50 mg/8 h p.o. of tramadol as rescue analgesia
Number of subjects: 40
Study 15181066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg TU i.m.
Number of subjects: 28
Study 15181066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 ml castor oil i.m.)
Number of subjects: 28
Study 14630678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capecitabine 1250 mg/m² twice daily, days 1-14 every 21 days
Number of subjects: 1967
Study 14630678 — intervention group
Group type: COMPARATOR
Intervention: i.v. bolus 5-FU 425 mg/m² with i.v. leucovorin 20 mg/m² on days 1-5, repeated every 28 days
Number of subjects: 1967
Study 10468217 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 2 g/d combined with L-ascorbic acid 3 g/d for 50 days
Number of subjects: 0
Study 10468217 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 7572007 — intervention group
Group type: EXPERIMENTAL
Intervention: dopexamine (2 micrograms.kg‐1 min‐1)
Number of subjects: 19
Study 7572007 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 2144260 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 79300 (25 or 50 mg p.o.)
Number of subjects: 6
Study 2144260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7350036 — intervention group
Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid (CCDA)
Number of subjects: 8
Study 7350036 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilron (750 mg/day)
Number of subjects: 8
Study 7350036 — intervention group
Group type: COMPARATOR
Intervention: Control periods
Number of subjects: 8
Study 31696369 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted active visualization intervention
Number of subjects: 28
Study 31696369 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 28
Study 28860012 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of rocuronium (continuous-NMB-group)
Number of subjects: 63
Study 28860012 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of rocuronium (bolus-NMB-group)
Number of subjects: 63
Study 25370322 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Number of subjects: 122
Study 25370322 — intervention group
Group type: COMPARATOR
Intervention: Insulin Aspart
Number of subjects: 122
Study 24306705 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanteric flip osteotomy
Number of subjects: 50
Study 24306705 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard posterior approach
Number of subjects: 50
Study 24306705 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified posterior approach
Number of subjects: 50
Study 21293136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen's fundoplication
Number of subjects: 64
Study 21293136 — intervention group
Group type: COMPARATOR
Intervention: Dor fundoplication
Number of subjects: 64
Study 18705632 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid 20% cream
Number of subjects: 24
Study 18705632 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 0.75% cream
Number of subjects: 24
Study 18705632 — intervention group
Group type: COMPARATOR
Intervention: Permethrin 5% cream
Number of subjects: 24
Study 18705632 — intervention group
Group type: EXPERIMENTAL
Intervention: All topical creams
Number of subjects: 24
Study 17096661 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet Dynamic Discrimination algorithm (Medtronic, Minneapolis, MN, USA) with a match threshold of 70%, operating in ON mode.
Number of subjects: 1122
Study 15480125 — intervention group
Group type: EXPERIMENTAL
Intervention: Health policy research initiatives
Number of subjects: 0
Study 15480125 — intervention group
Group type: EXPERIMENTAL
Intervention: Current research initiatives
Number of subjects: 0
Study 15480125 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy development
Number of subjects: 0
Study 15480125 — intervention group
Group type: EXPERIMENTAL
Intervention: Study methodology
Number of subjects: 0
Study 11709782 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous CCR5 Delta32
Number of subjects: 354
Study 11709782 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF-1 homozygous 3'A variant
Number of subjects: 354
Study 11709782 — intervention group
Group type: COMPARATOR
Intervention: Wild type (+) and variant genotypes
Number of subjects: 354
Study 9536541 — intervention group
Group type: COMPARATOR
Intervention: Topical lithium succinate ointment (Efalith), applied twice daily.
Number of subjects: 0
Study 9536541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 0
Study 8195977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m‐MDP (20 mCi) injection and gamma-camera scanning
Number of subjects: 26
Study 8195977 — intervention group
Group type: COMPARATOR
Intervention: Blade and screw type implants using the non‐submerged, one‐stage technique
Number of subjects: 26
Study 29101865 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-parenting breastfeeding support intervention including in-hospital discussion, breastfeeding booklet, co-parenting workbook, website, DVD, supportive emails, and proactive telephone call.
Number of subjects: 214
Study 27464900 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally Adapted Personal Protective Equipment
Number of subjects: 45
Study 27464900 — intervention group
Group type: COMPARATOR
Intervention: Daily Practice Clothing
Number of subjects: 45
Study 24002929 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (low dose): 0.125 mg/kg/min (1 min) loading followed by 0.02 mg/kg/min (20 min) continuous infusion
Number of subjects: 20
Study 24002929 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (high dose): 0.25 mg/kg/min (1 min) loading followed by 0.04 mg/kg/min (20 min) continuous infusion
Number of subjects: 20
Study 22842835 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) for three months, twice a week, focusing on lower limb muscles
Number of subjects: 43
Study 22842835 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 43
Study 20542898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mg, 2-4 hours prior to surgery)
Number of subjects: 141
Study 20542898 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 mg, 6-8 hours prior to surgery)
Number of subjects: 141
Study 20542898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 mg, 6-8 hours prior to surgery)
Number of subjects: 141
Study 18704361 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastography-guided biopsy
Number of subjects: 351
Study 18704361 — intervention group
Group type: COMPARATOR
Intervention: Classic TRUS-guided 10-core biopsy
Number of subjects: 351
Study 18704361 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastography in T1c subgroup
Number of subjects: 351
Study 18704361 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastography prediction of histopathologic findings
Number of subjects: 351